Advanced search
1 file | 1.43 MB

Rituximab: modes of action, remaining dispute and future perspective

(2014) FUTURE ONCOLOGY. 10(15). p.2481-2492
Author
Organization
Abstract
Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.
Keywords
rituximab, NON-HODGKINS-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, caspases, mechanism, cell death, apoptosis, ANTI-CD20 MONOCLONAL-ANTIBODY, B-CELL LYMPHOMA, FC-GAMMA-RIIIA, DRUG-INDUCED APOPTOSIS, FAS-INDUCED APOPTOSIS, IN-VIVO, SIGNALING PATHWAY, PHASE-I

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.43 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Abulayha, Abdulmunem, Amin Bredan, Hesham El Enshasy, and Ian Daniels. 2014. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” Future Oncology 10 (15): 2481–2492.
APA
Abulayha, Abdulmunem, Bredan, A., El Enshasy, H., & Daniels, I. (2014). Rituximab: modes of action, remaining dispute and future perspective. FUTURE ONCOLOGY, 10(15), 2481–2492.
Vancouver
1.
Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituximab: modes of action, remaining dispute and future perspective. FUTURE ONCOLOGY. 2014;10(15):2481–92.
MLA
Abulayha, Abdulmunem, Amin Bredan, Hesham El Enshasy, et al. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” FUTURE ONCOLOGY 10.15 (2014): 2481–2492. Print.
@article{5930159,
  abstract     = {Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.},
  author       = {Abulayha, Abdulmunem and Bredan, Amin and El Enshasy, Hesham and Daniels, Ian},
  issn         = {1479-6694},
  journal      = {FUTURE ONCOLOGY},
  keyword      = {rituximab,NON-HODGKINS-LYMPHOMA,CHRONIC LYMPHOCYTIC-LEUKEMIA,caspases,mechanism,cell death,apoptosis,ANTI-CD20 MONOCLONAL-ANTIBODY,B-CELL LYMPHOMA,FC-GAMMA-RIIIA,DRUG-INDUCED APOPTOSIS,FAS-INDUCED APOPTOSIS,IN-VIVO,SIGNALING PATHWAY,PHASE-I},
  language     = {eng},
  number       = {15},
  pages        = {2481--2492},
  title        = {Rituximab: modes of action, remaining dispute and future perspective},
  url          = {http://dx.doi.org/10.2217/fon.14.146},
  volume       = {10},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: